Additionally, silencing of the gene responsible for the enzyme in human A375 melanoma cells bearing BRAFV600E mutation has been shown to improve chemosensitivity to cisplatin; thus, paraoxonase-2 inhibitors may be of therapeutic value [98]. The gene discussed is PON2; the disease is melanoma.